ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Catabasis Pharmaceuticals Inc

Catabasis Pharmaceuticals Inc (CATB)

8,54
0,00
(0,00%)
Geschlossen 14 Oktober 10:00PM
0,00
0,00
(0,00%)
Nach Börsenschluss: -

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Current Price
8,54
Gebot
8,45
Fragen
8,63
Volumen
-
0,00 Tagesbereich 0,00
0,00 52-Wochen-Bereich 0,00
Marktkapitalisierung
Handelsende
8,54
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
-
Ausgegebene Aktien
36.296.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-4,25
Gewinn pro Aktie (EPS)
-2,01
Erlöse
-
Nettogewinn
-72,89M

Über Catabasis Pharmaceuticals Inc

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-

CATB Neueste Nachrichten

Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus

-- Astria Reflects Company’s Patient-Focused Mission -- -- Promising Lead Program STAR-0215 is in Preclinical Development to Prevent Attacks in Hereditary Angioedema -- -- Company to Begin...

Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. “We are...

Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the...

Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide...

Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide...

 Catabasis Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides a Corporate Update

 -- QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein, Progresses in Preclinical Development for the Treatment of Hereditary Angioedema -- -- Strong Cash...

Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

-- Recently Completed Acquisition of Quellis Biosciences Includes QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein in Preclinical Development for the...

Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences   

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide...

Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.

Acquisition Includes QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein in Preclinical Development for the Treatment of Hereditary Angioedema Company Plans to...

Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

-- Cash and Cash Equivalents Totaled $52.9 Million as of September 30, 2020 -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
CAMPCAMP4 Therapeutics Corporation
 10,75
(2.587,50%)
378,47k
TWGTop Wealth Group Holding Ltd
US$ 7,14
(233,64%)
154,23M
NIVFNewGenIvf Group Ltd
US$ 0,98
(63,42%)
58,51M
ATIFATIF Holdings Ltd
US$ 1,235
(58,33%)
3,85M
VERBVerb Technology Company Inc
US$ 7,91
(51,82%)
15,55M
BYUBAIYU Holdings Inc
US$ 0,299
(-35,28%)
11,11M
TURBTurbo Energy SA
US$ 2,1511
(-29,01%)
3,2M
SMSTDefiance Daily Target 1.5X Short MSTR ETF
US$ 7,898
(-23,62%)
993,33k
VEEAVeea Inc
US$ 3,27
(-23,24%)
284,95k
INHDInno Holdings Inc
US$ 3,74
(-22,41%)
257,75k
JTAIJet AI Inc
US$ 0,1009
(23,50%)
340,09M
CDTConduit Pharmaceuticals Inc
US$ 0,116
(13,28%)
270,97M
NVDANVIDIA Corporation
US$ 134,80
(-0,01%)
170,27M
LUXHLuxUrban Hotels Inc
US$ 0,0532
(5,35%)
165,94M
TWGTop Wealth Group Holding Ltd
US$ 7,14
(233,64%)
154,23M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock